Vimarsana
Biggest News Aggregation in the World

Jayanth Sridhar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jayanth Sridhar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jayanth Sridhar Today - Breaking & Trending Today

Eight Wealth Tips Just for Doctors - Vimarsana News

Eight Wealth Tips Just for Doctors

These money experts are doctors themselves and understand the unique financial needs of physicians. Here's what they suggest.

Black, Hispanic Applicants Underrepresented in Ophthalmology Fellowships - Vimarsana News

Black, Hispanic Applicants Underrepresented in Ophthalmology Fellowships

However, women and men had similar match rates

Ophthalmology Fellowship Match Rates Differ by Underrepresented in Medicine Status - Vimarsana News

Ophthalmology Fellowship Match Rates Differ by Underrepresented in Medicine Status

An analysis of ophthalmology subspecialty fellowships in 2021 revealed a lower match rate for applicants considered underrepresented in medicine.

Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA - Vimarsana News

Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA

In January 2023, the company had announced the successful completion of the full set of clinical studies of its proposed rituximab biosimilar candidate DRL_RI, with the intention to file in the United States, European Union and other regions Following dossier submission in April 2023, the regulatory agencies have now accepted the dossier for review

Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA - Vimarsana News

Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA

In January 2023, the company had announced the successful completion of the full set of clinical studies of its proposed rituximab biosimilar candidate DRL_RI, with the intention to file in the United States, European Union and other regionsFollowing dossier submission in April 2023, the regulatory agencies have now...